| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| BEAM - Beam Therapeutics Inc | BUY | 316 @ USD 34.55 | USD 10,918 | The ETF bought 316 new shares of BEAM (Beam Therapeutics Inc). The shares were bought for an average price of 34.55 compared to the previous average buy price of 22.1189. This is 56.2% higher than average price of previous purchases of BEAM. |
| DAWN - Day One Biopharmaceuticals Inc | BUY | 314 @ USD 10.59 | USD 3,325 | The ETF bought 314 new shares of DAWN (Day One Biopharmaceuticals Inc). The shares were bought for an average price of 10.59 compared to the previous average buy price of 7.77779. This is 36.2% higher than average price of previous purchases of DAWN. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 4.27 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 4.27. The average price that ABCL shares were previous bought at was USD 3.83815. The current market price is 11.3% higher than average price they were purchased at. The value of the holding in ABCL has fallen by USD 50,495 compared to the previous valuation of Abcellera Biologics Inc |
| ABUS - Arbutus Biopharma Corp | HOLD | 0 @ USD 4.74 | USD 0 | The current share valuation price of ABUS based on adjusted close was USD 4.74. The average price that ABUS shares were previous bought at was USD 3.88811. The current market price is 21.9% higher than average price they were purchased at. The value of the holding in ABUS has increased by USD 31,356 compared to the previous valuation of Arbutus Biopharma Corp however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 26.46 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 26.46. The average price that ACAD shares were previous bought at was USD 22.2857. The current market price is 18.7% higher than average price they were purchased at. The value of the holding in ACAD has fallen by USD 14,943 compared to the previous valuation of ACADIA Pharmaceuticals Inc |
| ACIU - AC Immune Ltd | HOLD | 0 @ USD 3.7 | USD 0 | The current share valuation price of ACIU based on adjusted close was USD 3.7. The average price that ACIU shares were previous bought at was USD 2.62418. The current market price is 41.0% higher than average price they were purchased at. The value of the holding in ACIU has increased by USD 13,010 compared to the previous valuation of AC Immune Ltd however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 66.75 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 66.75. The average price that ACLX shares were previous bought at was USD 71.9675. The current market price is -7.2% lower than average price they were purchased at. The value of the holding in ACLX has increased by USD 73,858 compared to the previous valuation of Arcellx Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| ACRS - Aclaris Therapeutics Inc | HOLD | 0 @ USD 2.71 | USD 0 | The current share valuation price of ACRS based on adjusted close was USD 2.71. The average price that ACRS shares were previous bought at was USD 2.70866. The current market price is 0.0% higher than average price they were purchased at. The value of the holding in ACRS has increased by USD 3,679 compared to the previous valuation of Aclaris Therapeutics Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| ADMA - ADMA Biologics Inc | HOLD | 0 @ USD 17.7 | USD 0 | The current share valuation price of ADMA based on adjusted close was USD 17.7. The average price that ADMA shares were previous bought at was USD 17.8269. The current market price is -0.7% lower than average price they were purchased at. The value of the holding in ADMA has fallen by USD 37,191 compared to the previous valuation of ADMA Biologics Inc |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 18.07 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 18.07. The average price that ADPT shares were previous bought at was USD 13.6175. The current market price is 32.7% higher than average price they were purchased at. The value of the holding in ADPT has fallen by USD 19,707 compared to the previous valuation of Adaptive Biotechnologies Corp |
| AGIO - Agios Pharm | HOLD | 0 @ USD 27.8 | USD 0 | The current share valuation price of AGIO based on adjusted close was USD 27.8. The average price that AGIO shares were previous bought at was USD 33.6378. The current market price is -17.4% lower than average price they were purchased at. The value of the holding in AGIO has fallen by USD 20,602 compared to the previous valuation of Agios Pharm |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 29.15 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 29.15. The average price that ALKS shares were previous bought at was USD 30.0307. The current market price is -2.9% lower than average price they were purchased at. The value of the holding in ALKS has fallen by USD 52,727 compared to the previous valuation of Alkermes Plc |
| ALLO - Allogene Therapeutics Inc | HOLD | 0 @ USD 1.64 | USD 0 | The current share valuation price of ALLO based on adjusted close was USD 1.64. The average price that ALLO shares were previous bought at was USD 1.35847. The current market price is 20.7% higher than average price they were purchased at. The value of the holding in ALLO has fallen by USD 4,755 compared to the previous valuation of Allogene Therapeutics Inc |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 369.96 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 369.96. The average price that ALNY shares were previous bought at was USD 388.269. The current market price is -4.7% lower than average price they were purchased at. The value of the holding in ALNY has fallen by USD 85,284 compared to the previous valuation of Alnylam Pharmaceuticals Inc |
| ALT - Altitude Group Plc | HOLD | 0 @ USD 4.01 | USD 0 | The current share valuation price of ALT based on adjusted close was USD 4.01. The average price that ALT shares were previous bought at was USD 4.88292. The current market price is -17.9% lower than average price they were purchased at. The value of the holding in ALT has fallen by USD 2,835 compared to the previous valuation of Altitude Group Plc |
| AMGN - Amgen Inc | HOLD | 0 @ USD 324.3 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 324.3. The average price that AMGN shares were previous bought at was USD 304.934. The current market price is 6.4% higher than average price they were purchased at. The value of the holding in AMGN has fallen by USD 265,210 compared to the previous valuation of Amgen Inc |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 12.6 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 12.6. The average price that AMLX shares were previous bought at was USD 9.25936. The current market price is 36.1% higher than average price they were purchased at. The value of the holding in AMLX has increased by USD 15,669 compared to the previous valuation of Amylyx Pharmaceuticals Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| AMPH - Amphastar P | HOLD | 0 @ USD 28.91 | USD 0 | The current share valuation price of AMPH based on adjusted close was USD 28.91. The average price that AMPH shares were previous bought at was USD 26.0141. The current market price is 11.1% higher than average price they were purchased at. The value of the holding in AMPH has fallen by USD 15,298 compared to the previous valuation of Amphastar P |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | HOLD | 0 @ USD 12.97 | USD 0 | The current share valuation price of AMRX based on adjusted close was USD 12.97. The average price that AMRX shares were previous bought at was USD 9.80229. The current market price is 32.3% higher than average price they were purchased at. The value of the holding in AMRX has fallen by USD 2,136 compared to the previous valuation of Amneal Pharmaceuticals, Inc. Class A Common Stock |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 48.125 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 48.125. The average price that ANAB shares were previous bought at was USD 29.2281. The current market price is 64.7% higher than average price they were purchased at. The value of the holding in ANAB has fallen by USD 17,025 compared to the previous valuation of AnaptysBio Inc |
| ANIP - ANI Pharmaceuticals Inc | HOLD | 0 @ USD 82.28 | USD 0 | The current share valuation price of ANIP based on adjusted close was USD 82.28. The average price that ANIP shares were previous bought at was USD 75.934. The current market price is 8.4% higher than average price they were purchased at. The value of the holding in ANIP has fallen by USD 31,586 compared to the previous valuation of ANI Pharmaceuticals Inc |
| APGE - Apogee Therapeutics, Inc. Common Stock | HOLD | 0 @ USD 79 | USD 0 | The current share valuation price of APGE based on adjusted close was USD 79. The average price that APGE shares were previous bought at was USD 57.4685. The current market price is 37.5% higher than average price they were purchased at. The value of the holding in APGE has increased by USD 50,296 compared to the previous valuation of Apogee Therapeutics, Inc. Common Stock however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| APLS - Apellis Pharmaceuticals Inc | HOLD | 0 @ USD 21.33 | USD 0 | The current share valuation price of APLS based on adjusted close was USD 21.33. The average price that APLS shares were previous bought at was USD 21.3486. The current market price is -0.1% lower than average price they were purchased at. The value of the holding in APLS has fallen by USD 160,753 compared to the previous valuation of Apellis Pharmaceuticals Inc |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 7.56999 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 7.56999. The average price that ARCT shares were previous bought at was USD 12.2734. The current market price is -38.3% lower than average price they were purchased at. The value of the holding in ARCT has increased by USD 825 compared to the previous valuation of Arcturus Therapeutics Holdings Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| ARDX - Ardelyx Inc | HOLD | 0 @ USD 7.04 | USD 0 | The current share valuation price of ARDX based on adjusted close was USD 7.04. The average price that ARDX shares were previous bought at was USD 5.00781. The current market price is 40.6% higher than average price they were purchased at. The value of the holding in ARDX has fallen by USD 52,820 compared to the previous valuation of Ardelyx Inc |
| ARGX - argenx NV ADR | HOLD | 0 @ USD 810.51 | USD 0 | The current share valuation price of ARGX based on adjusted close was USD 810.51. The average price that ARGX shares were previous bought at was USD 723.098. The current market price is 12.1% higher than average price they were purchased at. The value of the holding in ARGX has increased by USD 287,008 compared to the previous valuation of argenx NV ADR however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| ARQT - Arcutis Biotherapeutics Inc | HOLD | 0 @ USD 26.05 | USD 0 | The current share valuation price of ARQT based on adjusted close was USD 26.05. The average price that ARQT shares were previous bought at was USD 20.6034. The current market price is 26.4% higher than average price they were purchased at. The value of the holding in ARQT has fallen by USD 60,753 compared to the previous valuation of Arcutis Biotherapeutics Inc |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 12.29 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 12.29. The average price that ARVN shares were previous bought at was USD 10.0317. The current market price is 22.5% higher than average price they were purchased at. The value of the holding in ARVN has increased by USD 6,109 compared to the previous valuation of Arvinas Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| ARWR - Arrowhead Pharmaceuticals Inc | HOLD | 0 @ USD 65.545 | USD 0 | The current share valuation price of ARWR based on adjusted close was USD 65.545. The average price that ARWR shares were previous bought at was USD 31.7131. The current market price is 106.7% higher than average price they were purchased at. The value of the holding in ARWR has fallen by USD 35,526 compared to the previous valuation of Arrowhead Pharmaceuticals Inc |
| ASND - Ascendis Pharma AS | HOLD | 0 @ USD 215.05 | USD 0 | The current share valuation price of ASND based on adjusted close was USD 215.05. The average price that ASND shares were previous bought at was USD 187.563. The current market price is 14.7% higher than average price they were purchased at. The value of the holding in ASND has increased by USD 262,450 compared to the previous valuation of Ascendis Pharma AS however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 14.99 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 14.99. The average price that AUPH shares were previous bought at was USD 11.5716. The current market price is 29.5% higher than average price they were purchased at. The value of the holding in AUPH has fallen by USD 25,977 compared to the previous valuation of Aurinia Pharmaceuticals Inc |
| AUTL - Autolus Therapeutics Ltd | HOLD | 0 @ USD 1.37 | USD 0 | The current share valuation price of AUTL based on adjusted close was USD 1.37. The average price that AUTL shares were previous bought at was USD 1.729. The current market price is -20.8% lower than average price they were purchased at. The value of the holding in AUTL has fallen by USD 16,710 compared to the previous valuation of Autolus Therapeutics Ltd |
| AVIR - Atea Pharmaceuticals Inc | HOLD | 0 @ USD 3.51001 | USD 0 | The current share valuation price of AVIR based on adjusted close was USD 3.51001. The average price that AVIR shares were previous bought at was USD 3.25133. The current market price is 8.0% higher than average price they were purchased at. The value of the holding in AVIR has fallen by USD 6,065 compared to the previous valuation of Atea Pharmaceuticals Inc |
| AVXL - Anavex Life Sciences Corp | HOLD | 0 @ USD 4.64001 | USD 0 | The current share valuation price of AVXL based on adjusted close was USD 4.64001. The average price that AVXL shares were previous bought at was USD 7.84776. The current market price is -40.9% lower than average price they were purchased at. The value of the holding in AVXL has increased by USD 21,732 compared to the previous valuation of Anavex Life Sciences Corp however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 174.33 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 174.33. The average price that AXSM shares were previous bought at was USD 125.743. The current market price is 38.6% higher than average price they were purchased at. The value of the holding in AXSM has fallen by USD 85,290 compared to the previous valuation of Axsome Therapeutics Inc |
| AZN - AstraZeneca PLC | HOLD | 0 @ USD 94.51 | USD 0 | The current share valuation price of AZN based on adjusted close was USD 94.51. The average price that AZN shares were previous bought at was USD 80.3315. The current market price is 17.6% higher than average price they were purchased at. The value of the holding in AZN has increased by USD 349,005 compared to the previous valuation of AstraZeneca PLC however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| BBIO - BridgeBio Pharma Inc | HOLD | 0 @ USD 79.11 | USD 0 | The current share valuation price of BBIO based on adjusted close was USD 79.11. The average price that BBIO shares were previous bought at was USD 53.2474. The current market price is 48.6% higher than average price they were purchased at. The value of the holding in BBIO has increased by USD 297,213 compared to the previous valuation of BridgeBio Pharma Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 6.75 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 6.75. The average price that BCRX shares were previous bought at was USD 8.01472. The current market price is -15.8% lower than average price they were purchased at. The value of the holding in BCRX has fallen by USD 48,631 compared to the previous valuation of BioCryst Pharmaceuticals Inc |
| BCYC - Bicycle Therapeutics Ltd | HOLD | 0 @ USD 6.49 | USD 0 | The current share valuation price of BCYC based on adjusted close was USD 6.49. The average price that BCYC shares were previous bought at was USD 8.09788. The current market price is -19.9% lower than average price they were purchased at. The value of the holding in BCYC has fallen by USD 3,083 compared to the previous valuation of Bicycle Therapeutics Ltd |
| BIIB - Biogen Inc | HOLD | 0 @ USD 178.3 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 178.3. The average price that BIIB shares were previous bought at was USD 151.08. The current market price is 18.0% higher than average price they were purchased at. The value of the holding in BIIB has fallen by USD 730,611 compared to the previous valuation of Biogen Inc |
| BMRN - Biomarin Pharmaceutical Inc | HOLD | 0 @ USD 55.2 | USD 0 | The current share valuation price of BMRN based on adjusted close was USD 55.2. The average price that BMRN shares were previous bought at was USD 57.1077. The current market price is -3.3% lower than average price they were purchased at. The value of the holding in BMRN has fallen by USD 327,625 compared to the previous valuation of Biomarin Pharmaceutical Inc |
| BNTX - BioNTech SE | HOLD | 0 @ USD 107.19 | USD 0 | The current share valuation price of BNTX based on adjusted close was USD 107.19. The average price that BNTX shares were previous bought at was USD 102.75. The current market price is 4.3% higher than average price they were purchased at. The value of the holding in BNTX has increased by USD 344,152 compared to the previous valuation of BioNTech SE however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| CABA - Cabaletta Bio Inc | HOLD | 0 @ USD 2.15 | USD 0 | The current share valuation price of CABA based on adjusted close was USD 2.15. The average price that CABA shares were previous bought at was USD 2.15114. The current market price is -0.1% lower than average price they were purchased at. The value of the holding in CABA has fallen by USD 3,922 compared to the previous valuation of Cabaletta Bio Inc |
| CGEM - Cullinan Oncology LLC | HOLD | 0 @ USD 10.73 | USD 0 | The current share valuation price of CGEM based on adjusted close was USD 10.73. The average price that CGEM shares were previous bought at was USD 8.67221. The current market price is 23.7% higher than average price they were purchased at. The value of the holding in CGEM has increased by USD 4,731 compared to the previous valuation of Cullinan Oncology LLC however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 52.58 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 52.58. The average price that CGON shares were previous bought at was USD 33.7315. The current market price is 55.9% higher than average price they were purchased at. The value of the holding in CGON has fallen by USD 62,177 compared to the previous valuation of CG Oncology, Inc. Common stock |
| CNTA - Centessa Pharmaceuticals PLC ADR | HOLD | 0 @ USD 22.22 | USD 0 | The current share valuation price of CNTA based on adjusted close was USD 22.22. The average price that CNTA shares were previous bought at was USD 19.7049. The current market price is 12.8% higher than average price they were purchased at. The value of the holding in CNTA has increased by USD 13,110 compared to the previous valuation of Centessa Pharmaceuticals PLC ADR however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| COGT - Cogent Biosciences Inc | HOLD | 0 @ USD 35.28 | USD 0 | The current share valuation price of COGT based on adjusted close was USD 35.28. The average price that COGT shares were previous bought at was USD 20.7154. The current market price is 70.3% higher than average price they were purchased at. The value of the holding in COGT has increased by USD 54,234 compared to the previous valuation of Cogent Biosciences Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| COLL - Collegium Pharmaceutical Inc | HOLD | 0 @ USD 47.28 | USD 0 | The current share valuation price of COLL based on adjusted close was USD 47.28. The average price that COLL shares were previous bought at was USD 36.1804. The current market price is 30.7% higher than average price they were purchased at. The value of the holding in COLL has fallen by USD 18,686 compared to the previous valuation of Collegium Pharmaceutical Inc |
| CRBU - Caribou Biosciences Inc | HOLD | 0 @ USD 1.59 | USD 0 | The current share valuation price of CRBU based on adjusted close was USD 1.59. The average price that CRBU shares were previous bought at was USD 1.6851. The current market price is -5.6% lower than average price they were purchased at. The value of the holding in CRBU has increased by USD 635 compared to the previous valuation of Caribou Biosciences Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| CRNX - Crinetics Pharmaceuticals Inc | HOLD | 0 @ USD 54.31 | USD 0 | The current share valuation price of CRNX based on adjusted close was USD 54.31. The average price that CRNX shares were previous bought at was USD 38.6547. The current market price is 40.5% higher than average price they were purchased at. The value of the holding in CRNX has fallen by USD 67,050 compared to the previous valuation of Crinetics Pharmaceuticals Inc |
| CRSP - Crispr Therapeutics AG | HOLD | 0 @ USD 56.18 | USD 0 | The current share valuation price of CRSP based on adjusted close was USD 56.18. The average price that CRSP shares were previous bought at was USD 53.2739. The current market price is 5.5% higher than average price they were purchased at. The value of the holding in CRSP has increased by USD 56,981 compared to the previous valuation of Crispr Therapeutics AG however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 39.64 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 39.64. The average price that CSTL shares were previous bought at was USD 26.9834. The current market price is 46.9% higher than average price they were purchased at. The value of the holding in CSTL has fallen by USD 396 compared to the previous valuation of Castle Biosciences Inc |
| CYTK - Cytokinetics Inc | HOLD | 0 @ USD 63.33 | USD 0 | The current share valuation price of CYTK based on adjusted close was USD 63.33. The average price that CYTK shares were previous bought at was USD 49.8063. The current market price is 27.2% higher than average price they were purchased at. The value of the holding in CYTK has fallen by USD 108,823 compared to the previous valuation of Cytokinetics Inc |
| DNLI - Denali Therapeutics Inc | HOLD | 0 @ USD 18.11 | USD 0 | The current share valuation price of DNLI based on adjusted close was USD 18.11. The average price that DNLI shares were previous bought at was USD 16.2457. The current market price is 11.5% higher than average price they were purchased at. The value of the holding in DNLI has increased by USD 15,943 compared to the previous valuation of Denali Therapeutics Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 15.72 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 15.72. The average price that DVAX shares were previous bought at was USD 10.839. The current market price is 45.0% higher than average price they were purchased at. The value of the holding in DVAX has increased by USD 3,191 compared to the previous valuation of Dynavax Technologies Corporation however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| DYN - Dyne Therapeutics Inc | HOLD | 0 @ USD 17.04 | USD 0 | The current share valuation price of DYN based on adjusted close was USD 17.04. The average price that DYN shares were previous bought at was USD 15.0294. The current market price is 13.4% higher than average price they were purchased at. The value of the holding in DYN has fallen by USD 40,755 compared to the previous valuation of Dyne Therapeutics Inc |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | HOLD | 0 @ USD 17.04 | USD 0 | The current share valuation price of DYN based on adjusted close was USD 17.04. The average price that DYN shares were previous bought at was USD 15.0294. The current market price is 13.4% higher than average price they were purchased at. The value of the holding in DYN has fallen by USD 40,755 compared to the previous valuation of DYNAGREEN EN.PR.GR.H YC 1 |
| EDIT - Editas Medicine Inc | HOLD | 0 @ USD 2.09 | USD 0 | The current share valuation price of EDIT based on adjusted close was USD 2.09. The average price that EDIT shares were previous bought at was USD 2.58726. The current market price is -19.2% lower than average price they were purchased at. The value of the holding in EDIT has fallen by USD 2,777 compared to the previous valuation of Editas Medicine Inc |
| ELVN - Enliven Therapeutics Inc. | HOLD | 0 @ USD 25.75 | USD 0 | The current share valuation price of ELVN based on adjusted close was USD 25.75. The average price that ELVN shares were previous bought at was USD 20.9247. The current market price is 23.1% higher than average price they were purchased at. The value of the holding in ELVN has increased by USD 28,664 compared to the previous valuation of Enliven Therapeutics Inc. however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| EOLS - Evolus Inc | HOLD | 0 @ USD 5.71999 | USD 0 | The current share valuation price of EOLS based on adjusted close was USD 5.71999. The average price that EOLS shares were previous bought at was USD 8.46704. The current market price is -32.4% lower than average price they were purchased at. The value of the holding in EOLS has fallen by USD 2,202 compared to the previous valuation of Evolus Inc |
| ERAS - Erasca Inc | HOLD | 0 @ USD 7.505 | USD 0 | The current share valuation price of ERAS based on adjusted close was USD 7.505. The average price that ERAS shares were previous bought at was USD 2.1706. The current market price is 245.8% higher than average price they were purchased at. The value of the holding in ERAS has increased by USD 245,716 compared to the previous valuation of Erasca Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| EWTX - Edgewise Therapeutics Inc | HOLD | 0 @ USD 24.95 | USD 0 | The current share valuation price of EWTX based on adjusted close was USD 24.95. The average price that EWTX shares were previous bought at was USD 18.2626. The current market price is 36.6% higher than average price they were purchased at. The value of the holding in EWTX has increased by USD 58,982 compared to the previous valuation of Edgewise Therapeutics Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 44.08 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 44.08. The average price that EXEL shares were previous bought at was USD 41.8256. The current market price is 5.4% higher than average price they were purchased at. The value of the holding in EXEL has increased by USD 3,643 compared to the previous valuation of Exelixis Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| FDMT - 4D Molecular Therapeutics Inc | HOLD | 0 @ USD 7.86 | USD 0 | The current share valuation price of FDMT based on adjusted close was USD 7.86. The average price that FDMT shares were previous bought at was USD 7.83968. The current market price is 0.3% higher than average price they were purchased at. The value of the holding in FDMT has increased by USD 13,001 compared to the previous valuation of 4D Molecular Therapeutics Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| FOLD - Amicus Therapeutics Inc | HOLD | 0 @ USD 14.32 | USD 0 | The current share valuation price of FOLD based on adjusted close was USD 14.32. The average price that FOLD shares were previous bought at was USD 8.35375. The current market price is 71.4% higher than average price they were purchased at. The value of the holding in FOLD has increased by USD 8,384 compared to the previous valuation of Amicus Therapeutics Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 17.37 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 17.37. The average price that FTRE shares were previous bought at was USD 8.87603. The current market price is 95.7% higher than average price they were purchased at. The value of the holding in FTRE has fallen by USD 64,556 compared to the previous valuation of Fortrea Holdings Inc. |
| FULC - Fulcrum Therapeutics Inc | HOLD | 0 @ USD 10.25 | USD 0 | The current share valuation price of FULC based on adjusted close was USD 10.25. The average price that FULC shares were previous bought at was USD 10.0878. The current market price is 1.6% higher than average price they were purchased at. The value of the holding in FULC has increased by USD 27,208 compared to the previous valuation of Fulcrum Therapeutics Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| GERN - Geron Corporation | HOLD | 0 @ USD 1.31 | USD 0 | The current share valuation price of GERN based on adjusted close was USD 1.31. The average price that GERN shares were previous bought at was USD 1.4426. The current market price is -9.2% lower than average price they were purchased at. The value of the holding in GERN has fallen by USD 50,835 compared to the previous valuation of Geron Corporation |
| GH - Guardant Health Inc | HOLD | 0 @ USD 106.89 | USD 0 | The current share valuation price of GH based on adjusted close was USD 106.89. The average price that GH shares were previous bought at was USD 70.5631. The current market price is 51.5% higher than average price they were purchased at. The value of the holding in GH has fallen by USD 59,773 compared to the previous valuation of Guardant Health Inc |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 121.76 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 121.76. The average price that GILD shares were previous bought at was USD 117.839. The current market price is 3.3% higher than average price they were purchased at. The value of the holding in GILD has fallen by USD 493,207 compared to the previous valuation of Guild Esports Plc |
| GLPG - Galapagos NV ADR | HOLD | 0 @ USD 33.2501 | USD 0 | The current share valuation price of GLPG based on adjusted close was USD 33.2501. The average price that GLPG shares were previous bought at was USD 29.7943. The current market price is 11.6% higher than average price they were purchased at. The value of the holding in GLPG has increased by USD 1,328 compared to the previous valuation of Galapagos NV ADR however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| GLPG - Galapagos N.V. | HOLD | 0 @ USD 33.2501 | USD 0 | The current share valuation price of GLPG based on adjusted close was USD 33.2501. The average price that GLPG shares were previous bought at was USD 29.7943. The current market price is 11.6% higher than average price they were purchased at. The value of the holding in GLPG has increased by USD 1,328 compared to the previous valuation of Galapagos N.V. however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| GMAB - Genmab AS | HOLD | 0 @ USD 33.87 | USD 0 | The current share valuation price of GMAB based on adjusted close was USD 33.87. The average price that GMAB shares were previous bought at was USD 28.4228. The current market price is 19.2% higher than average price they were purchased at. The value of the holding in GMAB has fallen by USD 3,177 compared to the previous valuation of Genmab AS |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | HOLD | 0 @ USD 77.92 | USD 0 | The current share valuation price of GPCR based on adjusted close was USD 77.92. The average price that GPCR shares were previous bought at was USD 32.488. The current market price is 139.8% higher than average price they were purchased at. The value of the holding in GPCR has increased by USD 388,615 compared to the previous valuation of Structure Therapeutics Inc. American Depositary Shares however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| GRAL - GRAIL, LLC | HOLD | 0 @ USD 101.97 | USD 0 | The current share valuation price of GRAL based on adjusted close was USD 101.97. The average price that GRAL shares were previous bought at was USD 65.9605. The current market price is 54.6% higher than average price they were purchased at. The value of the holding in GRAL has fallen by USD 104,433 compared to the previous valuation of GRAIL, LLC |
| GRFS - Grifols SA ADR | HOLD | 0 @ USD 8.84 | USD 0 | The current share valuation price of GRFS based on adjusted close was USD 8.84. The average price that GRFS shares were previous bought at was USD 9.17947. The current market price is -3.7% lower than average price they were purchased at. The value of the holding in GRFS has fallen by USD 24,861 compared to the previous valuation of Grifols SA ADR |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 71.67 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 71.67. The average price that HALO shares were previous bought at was USD 62.0952. The current market price is 15.4% higher than average price they were purchased at. The value of the holding in HALO has fallen by USD 59,925 compared to the previous valuation of Halozyme Therapeutics Inc |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 35.76 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 35.76. The average price that HRMY shares were previous bought at was USD 33.5761. The current market price is 6.5% higher than average price they were purchased at. The value of the holding in HRMY has fallen by USD 98,218 compared to the previous valuation of Harmony Biosciences Holdings |
| HROW - Harrow Health Inc | HOLD | 0 @ USD 47.19 | USD 0 | The current share valuation price of HROW based on adjusted close was USD 47.19. The average price that HROW shares were previous bought at was USD 37.627. The current market price is 25.4% higher than average price they were purchased at. The value of the holding in HROW has fallen by USD 16,356 compared to the previous valuation of Harrow Health Inc |
| HUMA - Humacyte Inc | HOLD | 0 @ USD 1.11 | USD 0 | The current share valuation price of HUMA based on adjusted close was USD 1.11. The average price that HUMA shares were previous bought at was USD 1.94961. The current market price is -43.1% lower than average price they were purchased at. The value of the holding in HUMA has fallen by USD 2,355 compared to the previous valuation of Humacyte Inc |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.82 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.82. The average price that IBRX shares were previous bought at was USD 2.61974. The current market price is 7.6% higher than average price they were purchased at. The value of the holding in IBRX has increased by USD 153,827 compared to the previous valuation of Immunitybio Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 35.09 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 35.09. The average price that IDYA shares were previous bought at was USD 26.6651. The current market price is 31.6% higher than average price they were purchased at. The value of the holding in IDYA has fallen by USD 104,237 compared to the previous valuation of Ideaya Biosciences Inc |
| ILMN - Illumina Inc | HOLD | 0 @ USD 146.99 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 146.99. The average price that ILMN shares were previous bought at was USD 107.188. The current market price is 37.1% higher than average price they were purchased at. The value of the holding in ILMN has increased by USD 149,495 compared to the previous valuation of Illumina Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| IMCR - Immunocore Holdings Ltd | HOLD | 0 @ USD 32.3 | USD 0 | The current share valuation price of IMCR based on adjusted close was USD 32.3. The average price that IMCR shares were previous bought at was USD 34.2866. The current market price is -5.8% lower than average price they were purchased at. The value of the holding in IMCR has fallen by USD 10,066 compared to the previous valuation of Immunocore Holdings Ltd |
| IMVT - Immunovant Inc | HOLD | 0 @ USD 26.18 | USD 0 | The current share valuation price of IMVT based on adjusted close was USD 26.18. The average price that IMVT shares were previous bought at was USD 19.4564. The current market price is 34.6% higher than average price they were purchased at. The value of the holding in IMVT has increased by USD 44,063 compared to the previous valuation of Immunovant Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| INCY - Incyte Corporation | HOLD | 0 @ USD 103.43 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 103.43. The average price that INCY shares were previous bought at was USD 82.6269. The current market price is 25.2% higher than average price they were purchased at. The value of the holding in INCY has fallen by USD 386,828 compared to the previous valuation of Incyte Corporation |
| INSM - Insmed Inc | HOLD | 0 @ USD 163.72 | USD 0 | The current share valuation price of INSM based on adjusted close was USD 163.72. The average price that INSM shares were previous bought at was USD 144.007. The current market price is 13.7% higher than average price they were purchased at. The value of the holding in INSM has fallen by USD 579,616 compared to the previous valuation of Insmed Inc |
| INVA - Innoviva Inc | HOLD | 0 @ USD 19.51 | USD 0 | The current share valuation price of INVA based on adjusted close was USD 19.51. The average price that INVA shares were previous bought at was USD 19.6862. The current market price is -0.9% lower than average price they were purchased at. The value of the holding in INVA has increased by USD 3,556 compared to the previous valuation of Innoviva Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| IONS - Ionis Pharmaceuticals Inc | HOLD | 0 @ USD 79.48 | USD 0 | The current share valuation price of IONS based on adjusted close was USD 79.48. The average price that IONS shares were previous bought at was USD 58.0795. The current market price is 36.8% higher than average price they were purchased at. The value of the holding in IONS has fallen by USD 239,909 compared to the previous valuation of Ionis Pharmaceuticals Inc |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2.35 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2.35. The average price that IOVA shares were previous bought at was USD 2.39898. The current market price is -2.0% lower than average price they were purchased at. The value of the holding in IOVA has fallen by USD 12,791 compared to the previous valuation of Iovance Biotherapeutics Inc |
| IRON - Ironveld Plc | HOLD | 0 @ USD 75.44 | USD 0 | The current share valuation price of IRON based on adjusted close was USD 75.44. The average price that IRON shares were previous bought at was USD 66.8137. The current market price is 12.9% higher than average price they were purchased at. The value of the holding in IRON has fallen by USD 91,068 compared to the previous valuation of Ironveld Plc |
| IRWD - Ironwood Pharmaceuticals Inc | HOLD | 0 @ USD 4.64 | USD 0 | The current share valuation price of IRWD based on adjusted close was USD 4.64. The average price that IRWD shares were previous bought at was USD 2.44484. The current market price is 89.8% higher than average price they were purchased at. The value of the holding in IRWD has increased by USD 18,783 compared to the previous valuation of Ironwood Pharmaceuticals Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 13.79 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 13.79. The average price that JANX shares were previous bought at was USD 25.8755. The current market price is -46.7% lower than average price they were purchased at. The value of the holding in JANX has fallen by USD 9,614 compared to the previous valuation of Janux Therapeutics Inc |
| JAZZ - Jazz Pharmaceuticals PLC | HOLD | 0 @ USD 162.43 | USD 0 | The current share valuation price of JAZZ based on adjusted close was USD 162.43. The average price that JAZZ shares were previous bought at was USD 136.993. The current market price is 18.6% higher than average price they were purchased at. The value of the holding in JAZZ has fallen by USD 51,605 compared to the previous valuation of Jazz Pharmaceuticals PLC |
| KALV - Kalvista Pharmaceuticals Inc | HOLD | 0 @ USD 14.94 | USD 0 | The current share valuation price of KALV based on adjusted close was USD 14.94. The average price that KALV shares were previous bought at was USD 13.6272. The current market price is 9.6% higher than average price they were purchased at. The value of the holding in KALV has fallen by USD 49,796 compared to the previous valuation of Kalvista Pharmaceuticals Inc |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 38.6 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 38.6. The average price that KNSA shares were previous bought at was USD 33.275. The current market price is 16.0% higher than average price they were purchased at. The value of the holding in KNSA has fallen by USD 77,248 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd |
| KROS - Keros Therapeutics Inc | HOLD | 0 @ USD 19.5 | USD 0 | The current share valuation price of KROS based on adjusted close was USD 19.5. The average price that KROS shares were previous bought at was USD 15.9612. The current market price is 22.2% higher than average price they were purchased at. The value of the holding in KROS has increased by USD 12,833 compared to the previous valuation of Keros Therapeutics Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| KRYS - Krystal Biotech Inc | HOLD | 0 @ USD 291.93 | USD 0 | The current share valuation price of KRYS based on adjusted close was USD 291.93. The average price that KRYS shares were previous bought at was USD 181.153. The current market price is 61.2% higher than average price they were purchased at. The value of the holding in KRYS has increased by USD 390,100 compared to the previous valuation of Krystal Biotech Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 9.21001 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 9.21001. The average price that KURA shares were previous bought at was USD 8.37516. The current market price is 10.0% higher than average price they were purchased at. The value of the holding in KURA has increased by USD 2,365 compared to the previous valuation of Kura Oncology Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| KYMR - Kymera Therapeutics Inc | HOLD | 0 @ USD 74.13 | USD 0 | The current share valuation price of KYMR based on adjusted close was USD 74.13. The average price that KYMR shares were previous bought at was USD 53.6481. The current market price is 38.2% higher than average price they were purchased at. The value of the holding in KYMR has increased by USD 50,839 compared to the previous valuation of Kymera Therapeutics Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| LEGN - Legend Biotech Corp | HOLD | 0 @ USD 22.57 | USD 0 | The current share valuation price of LEGN based on adjusted close was USD 22.57. The average price that LEGN shares were previous bought at was USD 32.1688. The current market price is -29.8% lower than average price they were purchased at. The value of the holding in LEGN has fallen by USD 64,646 compared to the previous valuation of Legend Biotech Corp |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 188.78 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 188.78. The average price that LGND shares were previous bought at was USD 151.69. The current market price is 24.5% higher than average price they were purchased at. The value of the holding in LGND has fallen by USD 241,080 compared to the previous valuation of Ligand Pharmaceuticals Incorporated |
| LYEL - Lyell Immunopharma Inc | HOLD | 0 @ USD 23.71 | USD 0 | The current share valuation price of LYEL based on adjusted close was USD 23.71. The average price that LYEL shares were previous bought at was USD 7.57449. The current market price is 213.0% higher than average price they were purchased at. The value of the holding in LYEL has fallen by USD 832 compared to the previous valuation of Lyell Immunopharma Inc |
| MDGL - Madrigal Pharmaceuticals Inc | HOLD | 0 @ USD 493.9 | USD 0 | The current share valuation price of MDGL based on adjusted close was USD 493.9. The average price that MDGL shares were previous bought at was USD 418.735. The current market price is 18.0% higher than average price they were purchased at. The value of the holding in MDGL has fallen by USD 256,634 compared to the previous valuation of Madrigal Pharmaceuticals Inc |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 608.43 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 608.43. The average price that MEDP shares were previous bought at was USD 451.909. The current market price is 34.6% higher than average price they were purchased at. The value of the holding in MEDP has increased by USD 176,452 compared to the previous valuation of Medpace Holdings Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| MGTX - MeiraGTx Holdings PLC | HOLD | 0 @ USD 7.38 | USD 0 | The current share valuation price of MGTX based on adjusted close was USD 7.38. The average price that MGTX shares were previous bought at was USD 7.42371. The current market price is -0.6% lower than average price they were purchased at. The value of the holding in MGTX has increased by USD 7,359 compared to the previous valuation of MeiraGTx Holdings PLC however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| MIRM - Mirum Pharmaceuticals Inc | HOLD | 0 @ USD 90.44 | USD 0 | The current share valuation price of MIRM based on adjusted close was USD 90.44. The average price that MIRM shares were previous bought at was USD 60.5024. The current market price is 49.5% higher than average price they were purchased at. The value of the holding in MIRM has increased by USD 32,823 compared to the previous valuation of Mirum Pharmaceuticals Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | HOLD | 0 @ USD 32.94 | USD 0 | The current share valuation price of MLYS based on adjusted close was USD 32.94. The average price that MLYS shares were previous bought at was USD 26.6195. The current market price is 23.7% higher than average price they were purchased at. The value of the holding in MLYS has fallen by USD 2,151 compared to the previous valuation of Mineralys Therapeutics, Inc. Common Stock |
| MNKD - MannKind Corp | HOLD | 0 @ USD 5.64 | USD 0 | The current share valuation price of MNKD based on adjusted close was USD 5.64. The average price that MNKD shares were previous bought at was USD 5.00486. The current market price is 12.7% higher than average price they were purchased at. The value of the holding in MNKD has fallen by USD 27,120 compared to the previous valuation of MannKind Corp |
| MNMD - Mind Medicine Inc | HOLD | 0 @ USD 14.87 | USD 0 | The current share valuation price of MNMD based on adjusted close was USD 14.87. The average price that MNMD shares were previous bought at was USD 10.5903. The current market price is 40.4% higher than average price they were purchased at. The value of the holding in MNMD has increased by USD 66,258 compared to the previous valuation of Mind Medicine Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| MRNA - Moderna Inc | HOLD | 0 @ USD 39.6 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 39.6. The average price that MRNA shares were previous bought at was USD 28.2218. The current market price is 40.3% higher than average price they were purchased at. The value of the holding in MRNA has increased by USD 1,528,923 compared to the previous valuation of Moderna Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 4.02 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 4.02. The average price that MRVI shares were previous bought at was USD 2.97419. The current market price is 35.2% higher than average price they were purchased at. The value of the holding in MRVI has increased by USD 7,880 compared to the previous valuation of Maravai Lifesciences Holdings Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 132.26 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 132.26. The average price that NBIX shares were previous bought at was USD 135.826. The current market price is -2.6% lower than average price they were purchased at. The value of the holding in NBIX has fallen by USD 27,097 compared to the previous valuation of Neurocrine Biosciences Inc |
| NRIX - Nurix Therapeutics Inc | HOLD | 0 @ USD 18.93 | USD 0 | The current share valuation price of NRIX based on adjusted close was USD 18.93. The average price that NRIX shares were previous bought at was USD 14.8055. The current market price is 27.9% higher than average price they were purchased at. The value of the holding in NRIX has increased by USD 37,880 compared to the previous valuation of Nurix Therapeutics Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| NTLA - Intellia Therapeutics Inc | HOLD | 0 @ USD 11.74 | USD 0 | The current share valuation price of NTLA based on adjusted close was USD 11.74. The average price that NTLA shares were previous bought at was USD 11.4018. The current market price is 3.0% higher than average price they were purchased at. The value of the holding in NTLA has increased by USD 24,276 compared to the previous valuation of Intellia Therapeutics Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| NUVL - Nuvalent Inc | HOLD | 0 @ USD 101.17 | USD 0 | The current share valuation price of NUVL based on adjusted close was USD 101.17. The average price that NUVL shares were previous bought at was USD 89.5216. The current market price is 13.0% higher than average price they were purchased at. The value of the holding in NUVL has increased by USD 98,261 compared to the previous valuation of Nuvalent Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| NVAX - Novavax Inc | HOLD | 0 @ USD 8.67 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 8.67. The average price that NVAX shares were previous bought at was USD 7.22433. The current market price is 20.0% higher than average price they were purchased at. The value of the holding in NVAX has increased by USD 101,349 compared to the previous valuation of Novavax Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 8.67 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 8.67. The average price that NVAX shares were previous bought at was USD 7.22433. The current market price is 20.0% higher than average price they were purchased at. The value of the holding in NVAX has increased by USD 101,349 compared to the previous valuation of Hana Microelectronics Public Company Limited however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 13.65 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 13.65. The average price that NVCR shares were previous bought at was USD 15.3899. The current market price is -11.3% lower than average price they were purchased at. The value of the holding in NVCR has fallen by USD 40,323 compared to the previous valuation of Novocure Ltd |
| OABI - OmniAb Inc. | HOLD | 0 @ USD 1.9 | USD 0 | The current share valuation price of OABI based on adjusted close was USD 1.9. The average price that OABI shares were previous bought at was USD 1.88534. The current market price is 0.8% higher than average price they were purchased at. The value of the holding in OABI has fallen by USD 893 compared to the previous valuation of OmniAb Inc. |
| OCUL - Ocular Therapeutix Inc | HOLD | 0 @ USD 10.43 | USD 0 | The current share valuation price of OCUL based on adjusted close was USD 10.43. The average price that OCUL shares were previous bought at was USD 11.0179. The current market price is -5.3% lower than average price they were purchased at. The value of the holding in OCUL has fallen by USD 37,632 compared to the previous valuation of Ocular Therapeutix Inc |
| OLMA - Olema Pharmaceuticals Inc | HOLD | 0 @ USD 27.89 | USD 0 | The current share valuation price of OLMA based on adjusted close was USD 27.89. The average price that OLMA shares were previous bought at was USD 13.2544. The current market price is 110.4% higher than average price they were purchased at. The value of the holding in OLMA has fallen by USD 48,090 compared to the previous valuation of Olema Pharmaceuticals Inc |
| ORIC - Oric Pharmaceuticals Inc | HOLD | 0 @ USD 10.14 | USD 0 | The current share valuation price of ORIC based on adjusted close was USD 10.14. The average price that ORIC shares were previous bought at was USD 10.6341. The current market price is -4.6% lower than average price they were purchased at. The value of the holding in ORIC has increased by USD 63,819 compared to the previous valuation of Oric Pharmaceuticals Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 2.13 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 2.13. The average price that PACB shares were previous bought at was USD 1.73676. The current market price is 22.6% higher than average price they were purchased at. The value of the holding in PACB has increased by USD 24,606 compared to the previous valuation of Pacific Biosciences of California however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| PAHC - Phibro Animal Health Corporation | HOLD | 0 @ USD 40.46 | USD 0 | The current share valuation price of PAHC based on adjusted close was USD 40.46. The average price that PAHC shares were previous bought at was USD 31.7929. The current market price is 27.3% higher than average price they were purchased at. The value of the holding in PAHC has increased by USD 9,120 compared to the previous valuation of Phibro Animal Health Corporation however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| PCRX - Pacira BioSciences, Inc. | HOLD | 0 @ USD 21.6 | USD 0 | The current share valuation price of PCRX based on adjusted close was USD 21.6. The average price that PCRX shares were previous bought at was USD 23.93. The current market price is -9.7% lower than average price they were purchased at. The value of the holding in PCRX has fallen by USD 38,876 compared to the previous valuation of Pacira BioSciences, Inc. |
| PCVX - Vaxcyte Inc | HOLD | 0 @ USD 46.02 | USD 0 | The current share valuation price of PCVX based on adjusted close was USD 46.02. The average price that PCVX shares were previous bought at was USD 45.2921. The current market price is 1.6% higher than average price they were purchased at. The value of the holding in PCVX has increased by USD 16,009 compared to the previous valuation of Vaxcyte Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| PGEN - Precigen Inc | HOLD | 0 @ USD 4.17 | USD 0 | The current share valuation price of PGEN based on adjusted close was USD 4.17. The average price that PGEN shares were previous bought at was USD 3.04752. The current market price is 36.8% higher than average price they were purchased at. The value of the holding in PGEN has increased by USD 8,413 compared to the previous valuation of Precigen Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| PHAT - Phathom Pharmaceuticals Inc | HOLD | 0 @ USD 15.63 | USD 0 | The current share valuation price of PHAT based on adjusted close was USD 15.63. The average price that PHAT shares were previous bought at was USD 10.7999. The current market price is 44.7% higher than average price they were purchased at. The value of the holding in PHAT has increased by USD 56,066 compared to the previous valuation of Phathom Pharmaceuticals Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| PHVS - Pharvaris BV | HOLD | 0 @ USD 26 | USD 0 | The current share valuation price of PHVS based on adjusted close was USD 26. The average price that PHVS shares were previous bought at was USD 25.8541. The current market price is 0.6% higher than average price they were purchased at. The value of the holding in PHVS has fallen by USD 4,352 compared to the previous valuation of Pharvaris BV |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 280.83 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 280.83. The average price that PRAX shares were previous bought at was USD 131.43. The current market price is 113.7% higher than average price they were purchased at. The value of the holding in PRAX has increased by USD 86,479 compared to the previous valuation of Praxis Precision Medicines Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| PRME - Prime Medicine, Inc. Common Stock | HOLD | 0 @ USD 4.16 | USD 0 | The current share valuation price of PRME based on adjusted close was USD 4.16. The average price that PRME shares were previous bought at was USD 3.87502. The current market price is 7.4% higher than average price they were purchased at. The value of the holding in PRME has fallen by USD 15,134 compared to the previous valuation of Prime Medicine, Inc. Common Stock |
| PRTA - Prothena Corporation plc | HOLD | 0 @ USD 8.97999 | USD 0 | The current share valuation price of PRTA based on adjusted close was USD 8.97999. The average price that PRTA shares were previous bought at was USD 9.50288. The current market price is -5.5% lower than average price they were purchased at. The value of the holding in PRTA has increased by USD 2,774 compared to the previous valuation of Prothena Corporation plc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 75.4 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 75.4. The average price that PTCT shares were previous bought at was USD 62.0785. The current market price is 21.5% higher than average price they were purchased at. The value of the holding in PTCT has fallen by USD 119,465 compared to the previous valuation of PTC Therapeutics Inc |
| PTGX - Protagonist Therapeutics Inc | HOLD | 0 @ USD 81.36 | USD 0 | The current share valuation price of PTGX based on adjusted close was USD 81.36. The average price that PTGX shares were previous bought at was USD 65.7972. The current market price is 23.7% higher than average price they were purchased at. The value of the holding in PTGX has increased by USD 47,148 compared to the previous valuation of Protagonist Therapeutics Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| QURE - Uniqure NV | HOLD | 0 @ USD 21.5 | USD 0 | The current share valuation price of QURE based on adjusted close was USD 21.5. The average price that QURE shares were previous bought at was USD 23.6814. The current market price is -9.2% lower than average price they were purchased at. The value of the holding in QURE has fallen by USD 65,176 compared to the previous valuation of Uniqure NV |
| RAPT - RAPT Therapeutics Inc | HOLD | 0 @ USD 34.06 | USD 0 | The current share valuation price of RAPT based on adjusted close was USD 34.06. The average price that RAPT shares were previous bought at was USD 33.3033. The current market price is 2.3% higher than average price they were purchased at. The value of the holding in RAPT has fallen by USD 6,401 compared to the previous valuation of RAPT Therapeutics Inc |
| RARE - Ultragenyx | HOLD | 0 @ USD 24.11 | USD 0 | The current share valuation price of RARE based on adjusted close was USD 24.11. The average price that RARE shares were previous bought at was USD 35.5165. The current market price is -32.1% lower than average price they were purchased at. The value of the holding in RARE has fallen by USD 17,043 compared to the previous valuation of Ultragenyx |
| RARE - WISETFWTMRARETFP | HOLD | 0 @ USD 24.11 | USD 0 | The current share valuation price of RARE based on adjusted close was USD 24.11. The average price that RARE shares were previous bought at was USD 35.5165. The current market price is -32.1% lower than average price they were purchased at. The value of the holding in RARE has fallen by USD 17,043 compared to the previous valuation of WISETFWTMRARETFP |
| RCKT - Rocket Pharmaceuticals Inc | HOLD | 0 @ USD 3.8 | USD 0 | The current share valuation price of RCKT based on adjusted close was USD 3.8. The average price that RCKT shares were previous bought at was USD 4.64262. The current market price is -18.1% lower than average price they were purchased at. The value of the holding in RCKT has increased by USD 15,443 compared to the previous valuation of Rocket Pharmaceuticals Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 758.91 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 758.91. The average price that REGN shares were previous bought at was USD 655.331. The current market price is 15.8% higher than average price they were purchased at. The value of the holding in REGN has fallen by USD 637,863 compared to the previous valuation of Regeneron Pharmaceuticals Inc |
| REPL - Replimune Group Inc | HOLD | 0 @ USD 8.04 | USD 0 | The current share valuation price of REPL based on adjusted close was USD 8.04. The average price that REPL shares were previous bought at was USD 9.18857. The current market price is -12.5% lower than average price they were purchased at. The value of the holding in REPL has fallen by USD 3,446 compared to the previous valuation of Replimune Group Inc |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 15.05 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 15.05. The average price that RGNX shares were previous bought at was USD 10.2305. The current market price is 47.1% higher than average price they were purchased at. The value of the holding in RGNX has fallen by USD 1,032 compared to the previous valuation of Regenxbio Inc |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 7.94 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 7.94. The average price that RLAY shares were previous bought at was USD 5.02462. The current market price is 58.0% higher than average price they were purchased at. The value of the holding in RLAY has increased by USD 16,484 compared to the previous valuation of Relay Therapeutics Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| RNA - Avidity Biosciences Inc | HOLD | 0 @ USD 72.43 | USD 0 | The current share valuation price of RNA based on adjusted close was USD 72.43. The average price that RNA shares were previous bought at was USD 51.802. The current market price is 39.8% higher than average price they were purchased at. The value of the holding in RNA has increased by USD 8,190 compared to the previous valuation of Avidity Biosciences Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| ROIV - Roivant Sciences Ltd | HOLD | 0 @ USD 23.44 | USD 0 | The current share valuation price of ROIV based on adjusted close was USD 23.44. The average price that ROIV shares were previous bought at was USD 15.5936. The current market price is 50.3% higher than average price they were purchased at. The value of the holding in ROIV has increased by USD 604,847 compared to the previous valuation of Roivant Sciences Ltd however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 40.36 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 40.36. The average price that RPRX shares were previous bought at was USD 36.8494. The current market price is 9.5% higher than average price they were purchased at. The value of the holding in RPRX has increased by USD 29,028 compared to the previous valuation of Royalty Pharma Plc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| RVMD - Revolution Medicines Inc | HOLD | 0 @ USD 119.95 | USD 0 | The current share valuation price of RVMD based on adjusted close was USD 119.95. The average price that RVMD shares were previous bought at was USD 52.4104. The current market price is 128.9% higher than average price they were purchased at. The value of the holding in RVMD has increased by USD 365,142 compared to the previous valuation of Revolution Medicines Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 4.69 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 4.69. The average price that RXRX shares were previous bought at was USD 5.27642. The current market price is -11.1% lower than average price they were purchased at. The value of the holding in RXRX has fallen by USD 41,920 compared to the previous valuation of Recursion Pharmaceuticals Inc |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 107.8 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 107.8. The average price that RYTM shares were previous bought at was USD 84.6529. The current market price is 27.3% higher than average price they were purchased at. The value of the holding in RYTM has increased by USD 131,946 compared to the previous valuation of Rhythm Pharmaceuticals Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| SANA - Sana Biotechnology Inc | HOLD | 0 @ USD 4.7 | USD 0 | The current share valuation price of SANA based on adjusted close was USD 4.7. The average price that SANA shares were previous bought at was USD 3.52698. The current market price is 33.3% higher than average price they were purchased at. The value of the holding in SANA has increased by USD 21,596 compared to the previous valuation of Sana Biotechnology Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| SIGA - SIGA Technologies Inc | HOLD | 0 @ USD 6.60001 | USD 0 | The current share valuation price of SIGA based on adjusted close was USD 6.60001. The average price that SIGA shares were previous bought at was USD 6.6268. The current market price is -0.4% lower than average price they were purchased at. The value of the holding in SIGA has increased by USD 509 compared to the previous valuation of SIGA Technologies Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| SMMT - Summit Therapeutics PLC | HOLD | 0 @ USD 16.81 | USD 0 | The current share valuation price of SMMT based on adjusted close was USD 16.81. The average price that SMMT shares were previous bought at was USD 20.2386. The current market price is -16.9% lower than average price they were purchased at. The value of the holding in SMMT has fallen by USD 116,333 compared to the previous valuation of Summit Therapeutics PLC |
| SNDX - Syndax Pharmaceuticals Inc | HOLD | 0 @ USD 20.47 | USD 0 | The current share valuation price of SNDX based on adjusted close was USD 20.47. The average price that SNDX shares were previous bought at was USD 14.411. The current market price is 42.0% higher than average price they were purchased at. The value of the holding in SNDX has fallen by USD 14,761 compared to the previous valuation of Syndax Pharmaceuticals Inc |
| SNY - Sanofi ADR | HOLD | 0 @ USD 47.2 | USD 0 | The current share valuation price of SNY based on adjusted close was USD 47.2. The average price that SNY shares were previous bought at was USD 49.8282. The current market price is -5.3% lower than average price they were purchased at. The value of the holding in SNY has fallen by USD 71,917 compared to the previous valuation of Sanofi ADR |
| SPRY - Silverback Therapeutics Inc | HOLD | 0 @ USD 11.31 | USD 0 | The current share valuation price of SPRY based on adjusted close was USD 11.31. The average price that SPRY shares were previous bought at was USD 12.2931. The current market price is -8.0% lower than average price they were purchased at. The value of the holding in SPRY has fallen by USD 4,701 compared to the previous valuation of Silverback Therapeutics Inc |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 21.46 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 21.46. The average price that SRPT shares were previous bought at was USD 29.9783. The current market price is -28.4% lower than average price they were purchased at. The value of the holding in SRPT has increased by USD 23,139 compared to the previous valuation of Sarepta Therapeutics Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| SRRK - Scholar Rock Holding Corp | HOLD | 0 @ USD 43.75 | USD 0 | The current share valuation price of SRRK based on adjusted close was USD 43.75. The average price that SRRK shares were previous bought at was USD 37.1472. The current market price is 17.8% higher than average price they were purchased at. The value of the holding in SRRK has increased by USD 13,315 compared to the previous valuation of Scholar Rock Holding Corp however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 30.58 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 30.58. The average price that STOK shares were previous bought at was USD 20.3345. The current market price is 50.4% higher than average price they were purchased at. The value of the holding in STOK has increased by USD 45,016 compared to the previous valuation of Stoke Therapeutics Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 51.45 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 51.45. The average price that SUPN shares were previous bought at was USD 40.0618. The current market price is 28.4% higher than average price they were purchased at. The value of the holding in SUPN has increased by USD 3,507 compared to the previous valuation of Supernus Pharmaceuticals Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| SVRA - Savara Inc | HOLD | 0 @ USD 5.92 | USD 0 | The current share valuation price of SVRA based on adjusted close was USD 5.92. The average price that SVRA shares were previous bought at was USD 4.31222. The current market price is 37.3% higher than average price they were purchased at. The value of the holding in SVRA has increased by USD 20,735 compared to the previous valuation of Savara Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| SYRE - Spyre Therapeutics Inc. | HOLD | 0 @ USD 31.53 | USD 0 | The current share valuation price of SYRE based on adjusted close was USD 31.53. The average price that SYRE shares were previous bought at was USD 24.9007. The current market price is 26.6% higher than average price they were purchased at. The value of the holding in SYRE has fallen by USD 66,951 compared to the previous valuation of Spyre Therapeutics Inc. |
| TARS - Tarsus Pharmaceuticals Inc | HOLD | 0 @ USD 75.73 | USD 0 | The current share valuation price of TARS based on adjusted close was USD 75.73. The average price that TARS shares were previous bought at was USD 57.8036. The current market price is 31.0% higher than average price they were purchased at. The value of the holding in TARS has increased by USD 5,768 compared to the previous valuation of Tarsus Pharmaceuticals Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| TBPH - Theravance Biopharma Inc | HOLD | 0 @ USD 20.33 | USD 0 | The current share valuation price of TBPH based on adjusted close was USD 20.33. The average price that TBPH shares were previous bought at was USD 13.8095. The current market price is 47.2% higher than average price they were purchased at. The value of the holding in TBPH has increased by USD 22,994 compared to the previous valuation of Theravance Biopharma Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| TERN - Tern Plc | HOLD | 0 @ USD 34.45 | USD 0 | The current share valuation price of TERN based on adjusted close was USD 34.45. The average price that TERN shares were previous bought at was USD 12.5748. The current market price is 174.0% higher than average price they were purchased at. The value of the holding in TERN has increased by USD 20,809 compared to the previous valuation of Tern Plc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.04749. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| TNGX - Tango Therapeutics Inc | HOLD | 0 @ USD 10.44 | USD 0 | The current share valuation price of TNGX based on adjusted close was USD 10.44. The average price that TNGX shares were previous bought at was USD 7.74389. The current market price is 34.8% higher than average price they were purchased at. The value of the holding in TNGX has fallen by USD 20,126 compared to the previous valuation of Tango Therapeutics Inc |
| TRDA - Entrada Therapeutics Inc | HOLD | 0 @ USD 10.46 | USD 0 | The current share valuation price of TRDA based on adjusted close was USD 10.46. The average price that TRDA shares were previous bought at was USD 8.33626. The current market price is 25.5% higher than average price they were purchased at. The value of the holding in TRDA has increased by USD 13,048 compared to the previous valuation of Entrada Therapeutics Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| TSHA - Taysha Gene Therapies Inc | HOLD | 0 @ USD 4.9 | USD 0 | The current share valuation price of TSHA based on adjusted close was USD 4.9. The average price that TSHA shares were previous bought at was USD 3.34071. The current market price is 46.7% higher than average price they were purchased at. The value of the holding in TSHA has increased by USD 7,444 compared to the previous valuation of Taysha Gene Therapies Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| TVTX - Travere Therapeutics Inc | HOLD | 0 @ USD 29.11 | USD 0 | The current share valuation price of TVTX based on adjusted close was USD 29.11. The average price that TVTX shares were previous bought at was USD 24.7883. The current market price is 17.4% higher than average price they were purchased at. The value of the holding in TVTX has fallen by USD 303,347 compared to the previous valuation of Travere Therapeutics Inc |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 40.22 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 40.22. The average price that TWST shares were previous bought at was USD 34.6233. The current market price is 16.2% higher than average price they were purchased at. The value of the holding in TWST has increased by USD 90,570 compared to the previous valuation of Twist Bioscience Corp however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 20.52 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 20.52. The average price that TXG shares were previous bought at was USD 13.8197. The current market price is 48.5% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 56,971 compared to the previous valuation of 10X Genomics Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| TXG - Terex Corporation | HOLD | 0 @ USD 20.52 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 20.52. The average price that TXG shares were previous bought at was USD 13.8197. The current market price is 48.5% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 56,971 compared to the previous valuation of Terex Corporation however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| URGN - UroGen Pharma Ltd | HOLD | 0 @ USD 19.83 | USD 0 | The current share valuation price of URGN based on adjusted close was USD 19.83. The average price that URGN shares were previous bought at was USD 17.167. The current market price is 15.5% higher than average price they were purchased at. The value of the holding in URGN has fallen by USD 51,521 compared to the previous valuation of UroGen Pharma Ltd |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 476.86 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 476.86. The average price that UTHR shares were previous bought at was USD 387.025. The current market price is 23.2% higher than average price they were purchased at. The value of the holding in UTHR has fallen by USD 161,775 compared to the previous valuation of United Therapeutics Corporation |
| VCEL - Vericel Corp Ord | HOLD | 0 @ USD 37.05 | USD 0 | The current share valuation price of VCEL based on adjusted close was USD 37.05. The average price that VCEL shares were previous bought at was USD 39.8117. The current market price is -6.9% lower than average price they were purchased at. The value of the holding in VCEL has increased by USD 15,806 compared to the previous valuation of Vericel Corp Ord however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 43.05 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 43.05. The average price that VCYT shares were previous bought at was USD 35.4504. The current market price is 21.4% higher than average price they were purchased at. The value of the holding in VCYT has fallen by USD 21,484 compared to the previous valuation of Veracyte Inc |
| VERA - Vera Therapeutics Inc | HOLD | 0 @ USD 49.1 | USD 0 | The current share valuation price of VERA based on adjusted close was USD 49.1. The average price that VERA shares were previous bought at was USD 31.0705. The current market price is 58.0% higher than average price they were purchased at. The value of the holding in VERA has increased by USD 114,671 compared to the previous valuation of Vera Therapeutics Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 6.31 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 6.31. The average price that VIR shares were previous bought at was USD 5.93692. The current market price is 6.3% higher than average price they were purchased at. The value of the holding in VIR has increased by USD 35,940 compared to the previous valuation of Vir Biotechnology Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| VIR - Vidrala S.A | HOLD | 0 @ USD 6.31 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 6.31. The average price that VIR shares were previous bought at was USD 5.93692. The current market price is 6.3% higher than average price they were purchased at. The value of the holding in VIR has increased by USD 35,940 compared to the previous valuation of Vidrala S.A however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 7.44 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 7.44. The average price that VNDA shares were previous bought at was USD 5.02503. The current market price is 48.1% higher than average price they were purchased at. The value of the holding in VNDA has increased by USD 1,192 compared to the previous valuation of Vanda Pharmaceuticals Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 454.67 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 454.67. The average price that VRTX shares were previous bought at was USD 444.379. The current market price is 2.3% higher than average price they were purchased at. The value of the holding in VRTX has fallen by USD 1,008,768 compared to the previous valuation of Vertex Pharmaceuticals Inc |
| VTRS - Viatris Inc | HOLD | 0 @ USD 13.37 | USD 0 | The current share valuation price of VTRS based on adjusted close was USD 13.37. The average price that VTRS shares were previous bought at was USD 10.0405. The current market price is 33.2% higher than average price they were purchased at. The value of the holding in VTRS has increased by USD 539,956 compared to the previous valuation of Viatris Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| VTYX - Ventyx Biosciences Inc | HOLD | 0 @ USD 13.86 | USD 0 | The current share valuation price of VTYX based on adjusted close was USD 13.86. The average price that VTYX shares were previous bought at was USD 12.66. The current market price is 9.5% higher than average price they were purchased at. The value of the holding in VTYX has increased by USD 969 compared to the previous valuation of Ventyx Biosciences Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| VYGR - Voyager Therapeutics Inc | HOLD | 0 @ USD 4.02 | USD 0 | The current share valuation price of VYGR based on adjusted close was USD 4.02. The average price that VYGR shares were previous bought at was USD 3.95042. The current market price is 1.8% higher than average price they were purchased at. The value of the holding in VYGR has increased by USD 4,469 compared to the previous valuation of Voyager Therapeutics Inc however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| WVE - Wave Life Sciences Ltd | HOLD | 0 @ USD 14.22 | USD 0 | The current share valuation price of WVE based on adjusted close was USD 14.22. The average price that WVE shares were previous bought at was USD 8.55672. The current market price is 66.2% higher than average price they were purchased at. The value of the holding in WVE has increased by USD 35,210 compared to the previous valuation of Wave Life Sciences Ltd however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| XENE - Xenon Pharmaceuticals Inc | HOLD | 0 @ USD 40.36 | USD 0 | The current share valuation price of XENE based on adjusted close was USD 40.36. The average price that XENE shares were previous bought at was USD 37.9168. The current market price is 6.4% higher than average price they were purchased at. The value of the holding in XENE has fallen by USD 45,679 compared to the previous valuation of Xenon Pharmaceuticals Inc |
| XERS - Xeris Pharmaceuticals Inc | HOLD | 0 @ USD 7.71 | USD 0 | The current share valuation price of XERS based on adjusted close was USD 7.71. The average price that XERS shares were previous bought at was USD 6.29691. The current market price is 22.4% higher than average price they were purchased at. The value of the holding in XERS has fallen by USD 18,034 compared to the previous valuation of Xeris Pharmaceuticals Inc |
| XNCR - Xencor Inc | HOLD | 0 @ USD 13.94 | USD 0 | The current share valuation price of XNCR based on adjusted close was USD 13.94. The average price that XNCR shares were previous bought at was USD 12.6873. The current market price is 9.9% higher than average price they were purchased at. The value of the holding in XNCR has fallen by USD 11,159 compared to the previous valuation of Xencor Inc |
| ZLAB - Zai Lab Ltd | HOLD | 0 @ USD 18.72 | USD 0 | The current share valuation price of ZLAB based on adjusted close was USD 18.72. The average price that ZLAB shares were previous bought at was USD 30.642. The current market price is -38.9% lower than average price they were purchased at. The value of the holding in ZLAB has increased by USD 8,775 compared to the previous valuation of Zai Lab Ltd however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 23.92 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 23.92. The average price that ZYME shares were previous bought at was USD 17.719. The current market price is 35.0% higher than average price they were purchased at. The value of the holding in ZYME has increased by USD 38,641 compared to the previous valuation of Zymeworks Inc. Common Stock however if the holding was sold on 2026-01-13 this would crystalise an overall loss. |